Sarah Cannon Research Institute | Strategic Alliance Partners

March 27, 2017

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the results of cohort G from the KEYNOTE-021 trial, which explored pembrolizumab (Keytruda) combined with pemetrexed/carboplatin as a frontline treatment for patients with nonsquamous non–small cell lung cancer (NSCLC).

March 20, 2017

Todd Bauer, MD, associate director, Drug Development, principal investigator, Sarah Cannon Research Institute, discusses how phase I clinical trial programs are evolving and becoming more beneficial for patients with cancer.

October 07, 2016

Howard A. “Skip” Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, a 2014 Giant of Cancer Care in Drug Development, discusses the biggest remaining challenges in treating patients with HER2-positive breast cancer.

October 06, 2016

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses necessary research oncologists should begin conducting in the space of HER2-positive breast cancer.

September 02, 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.

July 20, 2016

Denise A. Yardley, MD, discusses two novel agents on the horizon for HER2-positive breast cancer.

July 15, 2016

Saeed Rafii, MD, PhD, MRCP, discusses the PD-L1 inhibitor durvalumab, the encouraging findings of it in Study 1108, and the evolving landscape of bladder cancer.

June 23, 2016

Howard A. "Skip" Burris, MD, offers insight on patient-reported outcomes from the MARIANNE trial and highlights exciting advancements in the neoadjuvant landscape of HER2-positive breast cancer.

June 20, 2016

During the past 2 years, there have been a number of advancements in the treatment of metastatic breast cancer that include the development of novel agents and new strategies in several disease settings, resulting in improved outcomes for patients.

March 28, 2016

Erika P. Hamilton, MD, discusses the significance of these trials and the impact ONT-380 may have on the treatment paradigm of HER2-positive breast cancer.

December 24, 2015

Howard A. “Skip” Burris III, MD, offers his views on key developments in the oncology field.

August 18, 2015

Jeffrey R. Infante, MD, discusses the fully human PD-L1 IgG1 antibody avelumab, which demonstrated clinical activity in patients with previously treated, recurrent/refractory ovarian cancer in a phase Ib open-label expansion trial.

July 22, 2015

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer.

July 07, 2015

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, Drug Development Unit, Sarah Cannon Research Institute-United Kingdom, discusses the overall survival results of the COMBI-d study, which examined the combination of dabrafenib and trametinib for the treatment of patients with unresectable or metastatic BRAF V600-mutated melanoma.

July 01, 2015

OncLive® will team with Sarah Cannon, the global cancer enterprise of Hospital Corporation of America, as it further expands its Strategic Alliance Partnership Program for raising awareness of cancer treatment and research.

June 17, 2015

For insight on the potential of ONT-380 in HER2-positive breast cancer, OncLive spoke with the lead author of the primary phase Ib analysis, Erika P. Hamilton, MD.

June 16, 2015

Saeed Rafii, MD, PhD, MRCP, medical director, Sarah Cannon Research Institute, discusses factors that influence clinical outcomes to olaparib in patients with BRCA1/2-mutant ovarian cancer.

June 12, 2015

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

February 06, 2015

Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses how the approvals of idelalisib and ibrutinib will change treatment paradigms for chronic lymphocytic leukemia (CLL) and low-grade lymphoma.

January 29, 2015

Denise Yardley, MD, senior investigator, breast cancer research, Sarah Cannon Research Institute discusses the phase II FERGI study and how it can be applied to more than just breast cancer.